Ensysce Biosciences (ENSC) Amortization of Deferred Charges (2024 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Amortization of Deferred Charges of $300000.0 for Q1 2025, down 74.39% year-over-year from $1.2 million in Q1 2024, and up 1065.73% quarter-over-quarter from $25735.0 in Q2 2024.
Ensysce Biosciences (ENSC) Amortization of Deferred Charges (2024 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Amortization of Deferred Charges for 2 consecutive years, with $300000.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Amortization of Deferred Charges fell 74.39% year-over-year to $300000.0; the TTM figure through Dec 2025 stood at $300000.0 (down 74.94% YoY), while the FY2025 annual figure was $300000.0, down 74.94% from the prior year.
- Amortization of Deferred Charges advanced to $300000.0 in Q1 2025 per ENSC's latest filing, from $25735.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $1.2 million in Q1 2024 and bottomed at $25735.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Jun 30, 2024 | 25,735.00 |
| Jun 30, 2024 | 25,735.00 |
| Mar 31, 2024 | 1.17 Mn |
| Mar 31, 2024 | 1.17 Mn |